ProtoKinetix, Inc. (NASDAQ:PKTX) CEO Clarence Edward Smith purchased 1,250,000 shares of the business’s stock in a transaction on Friday, November 4th. The stock was bought at an average cost of $0.04 per share, for a total transaction of $50,000.00. Following the purchase, the chief executive officer now owns 45,570,500 shares of the company’s stock, valued at approximately $1,822,820. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Clarence Edward Smith also recently made the following trade(s):

  • On Friday, September 23rd, Clarence Edward Smith purchased 321,263 shares of ProtoKinetix stock. The stock was bought at an average cost of $0.06 per share, for a total transaction of $19,275.78.
  • On Thursday, September 15th, Clarence Edward Smith purchased 1,595,553 shares of ProtoKinetix stock. The stock was bought at an average cost of $0.04 per share, for a total transaction of $63,822.12.
  • On Thursday, August 25th, Clarence Edward Smith acquired 90,753 shares of ProtoKinetix stock. The stock was acquired at an average cost of $0.05 per share, for a total transaction of $4,537.65.

Shares of ProtoKinetix, Inc. (NASDAQ:PKTX) opened at 0.062 on Thursday. The company’s market cap is $13.81 million. The stock has a 50 day moving average of $0.06 and a 200-day moving average of $0.06. ProtoKinetix, Inc. has a 12 month low of $0.02 and a 12 month high of $0.12.

Insider Buying and Selling by Quarter for ProtoKinetix (NASDAQ:PKTX)

ProtoKinetix Company Profile

ProtoKinetix, Incorporated is a research and development-stage bio-technology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins, known as AAGPs. AFGP is found in nature as a compound produced by some fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures.

5 Day Chart for NASDAQ:PKTX

Receive News & Stock Ratings for ProtoKinetix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProtoKinetix Inc. and related stocks with our FREE daily email newsletter.